Company / Operating Cash Flow
BridgeBio Oncology Therapeutics, Inc. Operating Cash Flow History
FY2024-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
-$763.8K
FY2024
5-year range
-$763.8K / -$763.8K
FY2024-FY2024
Trend
-
vs FY2023
Sector context
#77 of 216
Health Care
What the data says
At -$763,820, BridgeBio Oncology Therapeutics, Inc.'s operating cash flow ranks #77 of 216 in the Health Care sector.
Based on SEC 10-K filings.
-$763,820 in FY2024.
Health Care sector context is included.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#77 of 216 in Health CareTop 36% of 216This company -$763.8K Sector average $659.0M
▼
-100.1% below sector average
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -0.01 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | -$763.8K | - |
| FY2023 | - | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026